Secondary immunodeficiency (SID) in patients with B-cell hematological malignancies is a
common condition that presents with recurrent infection. SID is due to both the inherent …

Secondary immunodeficiency (SID) can occur as a result of multiple factors, including
hematological malignancies, hematopoietic stem cell transplantation (HSCT) …

Objective Despite long‐standing safe and effective use of immunoglobulin replacement
therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary …

Real-world data are lacking to identify patients with secondary immunodeficiency (SID) who
may benefit most from anti-infective interventions. This retrospective analysis used the IQVIA …

Acquired hypogammaglobulinemia or secondary immunodeficiency (SID) occurs commonly
in hematological malignancies with increasing incidence and complexity in the era of …

Objectives Secondary antibody deficiency (SAD), associated with severe, recurrent or
persistent infections, is common in patients with haematological malignancies (HM), but …

Objective We aimed to describe the current management and outcomes of patients with
secondary immunodeficiencies (SID) on intravenous (IV) or subcutaneous (SC) …

Primary immunodeficiencies (PIDs), a heterogenous group of inborn errors of immunity, are
predetermined at birth but may evolve with age, leading to a variable clinical and laboratory …

Many primary immunodeficiency disorders (PIDD) are associated with elevated risks for
different types of cancer. Defective immunosurveillance mechanisms in PIDD and infection …

Secondary immunodeficiencies occur as a consequence of various diseases, including
hematological malignancies, and the use of pharmacological therapies, such as …